Skip to the stories
Wednesday, 18 November 2026
Saved

Next edition

18:16

Headlines

Medical Science

RIPK1 Inhibitors Match Placebo Safety in Human Clinical Trials

A systematic review of 16 clinical trials found that receptor-interacting protein kinase 1 inhibitors showed adverse event risks comparable to placebos while successfully reaching high target inhibition.

FTMQ Health, written by our newsroom0 views

Share

A systematic review and meta-analysis published in Cell Death Discovery found that receptor-interacting protein kinase 1 inhibitors do not increase adverse event risks compared to a placebo, Bioengineer.org reported. The study evaluated data across 16 clinical trials involving human patients and healthy volunteers. [1]

The pooled analysis evaluated the therapeutic safety, pharmacokinetic behavior, and pharmacodynamic effects of the RIPK1 inhibitor class in humans. Bioengineer.org reported that participants taking the inhibitors showed an incidence of adverse events comparable to those receiving a placebo, yielding an overall pooled risk ratio of 0.99. [1]

Researchers observed that RIPK1 inhibitors achieved up to 97 percent target inhibition in the randomized placebo-controlled trials, according to Bioengineer.org. The findings offer practical context on the drug class for potential use in treating inflammatory conditions. [1]

Chronic inflammatory demyelinating polyneuropathy is one example of an autoimmune condition involving peripheral nervous system damage. The disease causes progressive weakness alongside sensory impairment in the arms and legs. [2]

Share

In short

  • A systematic review analyzed data from 16 clinical trials evaluating RIPK1 inhibitors.
  • RIPK1 inhibitors achieved up to 97 percent target inhibition in human trials.
  • The overall pooled risk ratio for adverse events between RIPK1 inhibitors and placebos was 0.99.

Sources

Every paragraph above points to the numbered items it rests on. Read the originals here.

  1. [1]RIPK1 Inhibitors Match Placebo Safety in Human Inflammatory Disease TrialsBioengineer.org, 2d ago (the report this story comes from)

Background

  1. [2]Chronic inflammatory demyelinating polyneuropathy on Wikipedia

Our newsroom writes these reports with the help of software, from the 2 sources listed and nothing else, and checks them against those sources. Facts can still be wrong or move on; the originals are the record. Spotted a mistake? Write to daniel@monsterkong.com.

Earlier reports of ours on the same people and subjects.

More in Medical Science

Get the day in one email

Reports like this one, the top news of the last 24 hours, every morning. Free, one email a day; readers can comment under every report.

By signing up you agree to our terms and privacy policy. Unsubscribe any time.

Comments

Loading

Join the conversation

Comments are open to readers of our daily email: the top news of the last 24 hours, every morning, free. Sign up and the comment box opens.

Already on the list? Enter the same address and we will send a sign-in link.

By signing up you agree to our terms and privacy policy. Unsubscribe any time.